Considering that IL-1β is both an upstream and downstream gene of NF-κB [40], the present data indicate that baricitinib suppressed the IL-6 Amp [41], the amplification of these two pathways mediated by IL-6, during arthritis. This evidence concerns the gene NFKB1 and arthritic joint disease.